1. Home
  2. SDSTW vs IMNN Comparison

SDSTW vs IMNN Comparison

Compare SDSTW & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Stardust Power Inc. Warrant

SDSTW

Stardust Power Inc. Warrant

N/A

Current Price

$0.23

Market Cap

13.3M

Sector

N/A

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

N/A

Current Price

$3.10

Market Cap

11.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SDSTW
IMNN
Founded
N/A
1982
Country
United States
United States
Employees
8
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3M
11.0M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
SDSTW
IMNN
Price
$0.23
$3.10
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$182.61
AVG Volume (30 Days)
8.6K
18.9K
Earning Date
03-26-2025
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.00
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.02
$0.37
52 Week High
$0.30
$9.32

Technical Indicators

Market Signals
Indicator
SDSTW
IMNN
Relative Strength Index (RSI) 55.17 40.51
Support Level $0.17 $3.03
Resistance Level $0.30 $3.16
Average True Range (ATR) 0.02 0.23
MACD -0.00 -0.00
Stochastic Oscillator 100.00 13.79

Price Performance

Historical Comparison
SDSTW
IMNN

About SDSTW Stardust Power Inc. Warrant

Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Share on Social Networks: